Skip to main content
. Author manuscript; available in PMC: 2022 Feb 6.
Published in final edited form as: Bioconjug Chem. 2020 Jan 30;31(3):743–753. doi: 10.1021/acs.bioconjchem.9b00854

Figure 2. SEC HPLC analyses of DOTA-anti-CEA-Fab’-LND and DOTA-anti-CEA-LND.

Figure 2.

A. DOTA-anti-CEA Fab’-azide. B. DOTA-anti-CEA Fab’-azide clicked to DSPE-PEG2000-DBCO LND. C. Immunoreactivity of DOTA-anti-CEA Fab’-azide clicked to DSPE-PEG2000-DBCO LND after addition of 2-fold excess CEA. D. DOTA-anti-CEA-azide. E. DOTA-anti-CEA-azide clicked to DSPE-PEG2000-DBCO LND. F. Immunoreactivity of DOTA-anti-CEA-azide-DSPE-PEG2000-DBCO LND after addition of two-fold excess of CEA. Red= 214 nm. Blue- 240 nm.